Upcoming Post-Conference Perspectives: ASH 2021

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.